TY - JOUR

T1 - Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada

T2 - collaborative cohort analysis

AU - Obel, Niels

AU - Antiretroviral Therapy Cohort Collaboration (ART-CC)

PY - 2016

Y1 - 2016

N2 - OBJECTIVES: To estimate prognosis by viral subtype in HIV-1-infected individuals from start of antiretroviral therapy (ART) and after viral failure.DESIGN: Collaborative analysis of data from eight European and three Canadian cohorts.METHODS: Adults (N>20 000) who started triple ART between 1996 and 2012 and had data on viral subtype were followed for mortality. We estimated crude and adjusted (for age, sex, regimen, CD4 cell count, and AIDS at baseline, period of starting ART, stratified by cohort, region of origin and risk group) mortality hazard ratios (MHR) by subtype. We estimated MHR subsequent to viral failure defined as two HIV-RNA measurements greater than 500 copies/ml after achieving viral suppression.RESULTS: The most prevalent subtypes were B (15 419; 74%), C (2091; 10%), CRF02AG (1057; 5%), A (873; 4%), CRF01AE (506; 2.4%), G (359; 1.7%), and D (232; 1.1%). Subtypes were strongly patterned by region of origin and risk group. During 104 649 person-years of observation, 1172/20 784 patients died. Compared with subtype B, mortality was higher for subtype A, but similar for all other subtypes. MHR for A versus B were 1.13 (95% confidence interval 0.85,1.50) when stratified by cohort, increased to 1.78 (1.27,2.51) on stratification by region and risk, and attenuated to 1.59 (1.14,2.23) on adjustment for covariates. MHR for A versus B was 2.65 (1.64,4.28) and 0.95 (0.57,1.57) for patients who started ART with CD4 cell count below, or more than, 100 cells/μl, respectively. There was no difference in mortality between subtypes A, B and C after viral failure.CONCLUSION: Patients with subtype A had worse prognosis, an observation which may be confounded by socio-demographic factors.

AB - OBJECTIVES: To estimate prognosis by viral subtype in HIV-1-infected individuals from start of antiretroviral therapy (ART) and after viral failure.DESIGN: Collaborative analysis of data from eight European and three Canadian cohorts.METHODS: Adults (N>20 000) who started triple ART between 1996 and 2012 and had data on viral subtype were followed for mortality. We estimated crude and adjusted (for age, sex, regimen, CD4 cell count, and AIDS at baseline, period of starting ART, stratified by cohort, region of origin and risk group) mortality hazard ratios (MHR) by subtype. We estimated MHR subsequent to viral failure defined as two HIV-RNA measurements greater than 500 copies/ml after achieving viral suppression.RESULTS: The most prevalent subtypes were B (15 419; 74%), C (2091; 10%), CRF02AG (1057; 5%), A (873; 4%), CRF01AE (506; 2.4%), G (359; 1.7%), and D (232; 1.1%). Subtypes were strongly patterned by region of origin and risk group. During 104 649 person-years of observation, 1172/20 784 patients died. Compared with subtype B, mortality was higher for subtype A, but similar for all other subtypes. MHR for A versus B were 1.13 (95% confidence interval 0.85,1.50) when stratified by cohort, increased to 1.78 (1.27,2.51) on stratification by region and risk, and attenuated to 1.59 (1.14,2.23) on adjustment for covariates. MHR for A versus B was 2.65 (1.64,4.28) and 0.95 (0.57,1.57) for patients who started ART with CD4 cell count below, or more than, 100 cells/μl, respectively. There was no difference in mortality between subtypes A, B and C after viral failure.CONCLUSION: Patients with subtype A had worse prognosis, an observation which may be confounded by socio-demographic factors.

KW - Adult

KW - Anti-Retroviral Agents

KW - Canada

KW - Cohort Studies

KW - Cooperative Behavior

KW - Europe

KW - Female

KW - Genotype

KW - HIV Infections

KW - HIV-1

KW - Humans

KW - Male

KW - Middle Aged

KW - Prognosis

KW - Survival Analysis

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.1097/QAD.0000000000000941

DO - 10.1097/QAD.0000000000000941

M3 - Journal article

C2 - 26562844

VL - 30

SP - 503

EP - 513

JO - AIDS

JF - AIDS

SN - 1350-2840

IS - 3

ER -